Oncolys BioPharma Inc. (4588) Earnings: Sales Increase +16.6% YoY to 503 Million Yen with Operating Loss of 767 Million Yen

Oncolys BioPharma Inc. (4588) announced its financial results for the period, reporting net sales of 503 million yen, representing a +16.6% increase compared to the same period of the previous year. Meanwhile, the company posted an operating loss of 767 million yen, ordinary loss of 760 million yen, and a net loss of 762 million yen (earnings per share of -26.03 yen), reflecting ongoing investments in research and development.

From a financial perspective, the capital adequacy ratio stood at 72.1%, interest-bearing debt at 800 million yen, and retained earnings at -760 million yen. Operating cash flow was -1.02 billion yen and free cash flow was -990 million yen. On the other hand, cash and cash equivalents stood at 2.94 billion yen, maintaining a certain level of liquidity to support future research and business development initiatives.